NCT02601560View on ClinicalTrials.gov

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

August 20, 2016

Study Completion Date

November 3, 2016

Conditions
Coronary Artery Disease
Interventions
BIOLOGICAL

MEDI6012

Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.

BIOLOGICAL

Placebo SC

Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.

BIOLOGICAL

Placebo IV

Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.

Trial Locations (8)

22042

Research Site, Falls Church

27612

Research Site, Raleigh

27710

Research Site, Durham

32127

Research Site, Port Orange

32216

Research Site, Jacksonville

36207

Research Site, Anniston

45227

Research Site, Cincinnati

78229

Research Site, San Antonio

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT02601560 - To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease | Biotech Hunter | Biotech Hunter